Olema Falls After AstraZeneca's Etcamah Fails Late-Stage Breast Cancer Trial

Price ActionProduct / Tech
โดย Seeking Alpha·USGB·Read original
Summary · why it matters

Olema Pharmaceuticals shares dropped about 15% in after-hours trading Friday after AstraZeneca disclosed that its SERD and CERAN, Etcamah (camizestrant), failed as a first-line breast cancer treatment. Olema is developing its own estrogen receptor antagonist and selective estrogen receptor degrader, palazestrant. Palazestrant is in phase 3 development in a collaboration with Novartis as a first-line treatment in combination with the CDK 4/6 inhibitor Kisqali (ribociclib) for metastatic breast cancer, and it is also in phase 3 as a second- and third-line monotherapy.

Impact on stocks 3

Biotech & Genomic Medicine▼ · 3 stocks
AstraZeneca PLC
AZN
▼ NegativeTechnologyrelevance

AstraZeneca's SERD camizestrant (Ecamah) failed as a first-line breast cancer treatment in a late-stage trial.

Olema Pharmaceuticals Inc
OLMA
▼ NegativeCompetitionrelevance

Olema fell after AstraZeneca's rival SERD camizestrant failed a first-line breast cancer trial, raising doubts about the class and its own palazestrant.

Novartis AG
NOVN
± MixedCompetitionrelevance

Novartis is only mentioned as Olema's palazestrant collaboration partner; the rival SERD failure's read-through to its Kisqali combo is unclear.

© 2026 MarketDXNews